drugset / Trial / NCT00156962

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

NCT00156962

Phase 3 Terminated 850 enrolled Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to look at subject incidence of adverse events.

Timeline

Start
2005-04
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic